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Objectives. This study was performed to assess the effect of 
cigarette smoking cessation on overall mortality and the incidence 
of arrhythmic death in the population of the Cardiac Arrhythmia 
Suppression Trial (CAST). 
Background. Cigarette smoking is a known risk factor for 
sudden cardiac death. Some of the adverse ffects of smoking have 
been shown to dissipate with smoking cessation, but the time 
frame over which these changes occur and the population that 
stands to benefit have not been well delineated. CAST was a 
multiceuter double-blind placebo-controlled study to determine 
whether suppression of ventricular ectopic activity by means of 
antiarrhythmic drugs in patients with left ventricular dysfunction 
after acute myocardial infarction would reduce the incidence of 
arrhythmic death. 
Methods. Of 2,752 patients randomized to blinded therapy, 
1,026 were smoking at the time of their baseline xamination and 
completed a 4-month follow-up visit. Of these, 517 stopped 
smoking by the time of this visit ("quitters") and 509 continued to 
smoke ("smokers"). 
Results. Over a mean follow-up eriod of slightly <16 months, 
there were 17 arrhythmic deaths and 32 total deaths among the 
quitters versus 30 and 45, respectively, among the smokers; these 
differences were of marginal statistical significance. Most of the 
fatal events occurred in a group at high risk of ongoing ischemia: 
the 558 patients who did not have thrombolysis or undergo 
revascnlarization after their qualifying myocardial infarction. In 
this high risk cohort, smoking cessation greatly reduced the 
incidence of arrhythmic death and was associated with a statisti- 
cally significant benefit in survival. 
Conclusions. Smoking cessation was accompanied bya marked 
reduction in arrhythmic death and overall mortality that achieved 
statistical significance ina high risk cohort. These data imply that 
smoking cessation isimportant inrisk factor eduction in patients 
with advanced ischemic heart disease. 
(JAm Coil Cardioi 1995;26:1287-92) 
Cigarette smoking is a known risk factor for acute myocardial 
infarction and sudden cardiac death, but its role in the 
pathogenesis of these events is incompletely understood (1-9). 
Cigarette smoke is a complex mixture containing several 
ingredients that could be deleterious to the cardiovascular 
system. In particular, nicotine produces a marked elevation in 
serum catecholamine concentration that is potentially arrhyth- 
mogenic, especially in persons with ischemic heart disease. 
Some of the adverse cardiovascular effects of cigarette smoking 
have been shown to dissipate with smoking cessation (10-16). 
The present study was planned prospectively to investigate the 
effect of smoking cessation on mortality and the incidence of 
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arrhythmic death in the subjects of the Cardiac Arrhythmia 
Suppression Trial (CAST), a large cohort of high risk patients 
with frequent ventricular ectopic activity and left ventricular 
dysfunction after acute myocardial infarction. 
Methods  
The institutional committee on human research approved 
the study protocol in all participating institutions. A detailed 
description of the CAST methodology has been provided 
elsewhere (17-19). The initial part of the trial (CAST I), in 
which encainide and flecainide and moricizine were used, was 
begun on June 13, 1987 and was terminated on April 14, 1989. 
The CAST II trial, using three doses of moricizine, began on 
April 19, 1989, and was terminated on August 1, 1991. The 
following is a brief review of the more important aspects of the 
trial with more detailed information in the areas relevant to 
the present analysis. 
Patients. Patients <80 years of age were eligible for 
CAST I if they demonstrated an average of ->6 ventricular 
premature depolarizations/h on a baseline 24-h Holter ambu- 
lato~ electrocardiogram (ECG) and were found to have an 
ejection fraction -<55% within 90 days or -<40% within 2 years 
of a documented acute myocardial infarction. Specifically 
excluded were patients with -> 15 consecutive beats of ventric- 
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ular tachycardia ata rate of -> 120 beats/min >6 days after the 
infarction, patients with high grade atrioventricular block or 
symptomatic sinus node disease (in the absence of a perma- 
nent pacemaker) and those with conditions likely to limit life 
span (e.g., inoperable malignant neoplasm). Also excluded 
were patients receiving other antiarrhythmic drugs or those 
with contraindications to any of the study drugs. 
Eligibility criteria for CAST II were similar except that 
patients could only be recruited up to 90 days after acute 
myocardial infarction (using the same Holter criteria as in 
CAST I) and only if the left ventricular ejection fraction was 
-<0.40. In addition, disqualifying ventricular tachycardia was 
redefined to include runs -<30 s at a rate of -<120 beats/rain 
unassociated with symptoms. 
Open label titration in CAST I. After giving written in- 
formed consent, patients underwent an open label titration 
phase (averaging 15 days), during which up to two oral doses of 
three drugs (encainide, flecainide and moricizine) were evalu- 
ated. The titration was stopped as soon as a drug and dose 
were found that suppressed the arrhythmias. The criteria for 
suppression of arrhythmia were ->80% reduction of ventricular 
premature depolarizations and ->90% reduction of runs of 
unsustained ventricular tachycardia s measured by 24-h 
Holter recording. Patients whose arrhythmia ncreased uring 
the open label titration or who were intolerant of the drugs 
were not advanced to the randomized phase of the trial. 
Drug titration in CAST II. Baseline clinical data were 
recorded, and patients were randomized to receive ither low 
dose moricizine or its matching placebo for a 2-week period. 
This initial blinded, placebo-controlled, short-term exposure 
phase of the trial evaluated only the 1st 2 weeks of therapy. 
After 2 weeks, therapy was unblinded and the patients who had 
been treated with active medication were evaluated by ambu- 
latory ECG recording to determine whether ventricular pre- 
mature depolarizations were adequately suppressed. In pa- 
tients who had been treated with placebo (or delayed initiation 
of active therapy), active moricizine titration was begun and 
followed by evaluation with ambulatory ECG recording. 
Patients who had been treated with moricizine or matching 
placebo in CAST I simply continued their assigned treatment 
in CAST II. Patients who had been assigned to receive 
encainide, flecainide or placebo in CAST I and whose ectopic 
activity persisted after discontinuation f their assigned treat- 
ment were offered the opportunity to participate in CAST II 
and underwent the blinded 2-week trial as just described. 
Adequate suppression of ventricular premature depolariza- 
tions was defined as in CAST I. Three doses of moricizine were 
available for titration and if adequate suppression was not 
obtained with the initial dose, the second and, if necessary, the 
third dose were used as long as disqualifying adverse ffects or 
symptoms did not occur. 
Randomization and follow-up. Patients whose arrhythmias 
were suppressed were randomly assigned (in double-blind 
manner) to receive the dose of the drug that suppressed their 
ventricular ectopic activity or matching placebo by strata based 
on clinical center, left ventricular ejection fraction and length 
of time between the index myocardial infarction and the 
qualifying Holter recording. Patients were seen in follow-up at 
4-month intervals. 
Study design. Of the total of 2,752 patients who were 
randomly assigned to blinded therapy, 1,115 were smoking at 
the time of their qualifying myocardial infarction. Of these, 
1,026 had a complete 4-month follow-up visit and are the 
subject of the present report. Of the remaining 89 patients, 29 
(2.6%) died before their 4-month follow-up visit, 5 (0.4%) 
withdrew from the study, 33 (3.0%) had not had the scheduled 
4-month visit by the time the study ended and 22 (2.0%) had 
incomplete follow-up information. Smoking status (including 
the number of cigarettes moked) was determined by the 
physician or nurse coordinator at the time of the baseline 
examination, at the 4-month follow-up visit and yearly there- 
after. For the purpose of the present analyses we defined 
"quitters" as persons who stopped smoking between the time 
of their qualifying myocardial infarction and their 4-month 
follow-up visit and "present smokers" as those who continued 
to smoke until that time. In keeping with the original CAST 
hypothesis, our primary study end point was arrhythmic death/ 
resuscitated cardiac arrest (subsequently referred to as at- 
rhythmic death) and our secondary end point was total 
mortality/resuscitated cardiac arrest (subsequently referred to 
as total mortality). For purposes of analysis, arrhythmic death 
included witnessed instantaneous death, unwitnessed eath 
with no preceding change in symptoms for which no other cause 
could be ascribed, resuscitated cardiac arrest or witnessed 
death with anginalikc symptoms or symptoms suggestive of a 
cardiac arrhythmia (e.g., syncope, palpitation or dizziness) in 
the absence of severe congestive heart failure or shock. 
Statistical methods. The clinical and demographic charac- 
teristics at baseline were compared for the present smokers 
and the quitters by using standard chi-square statistics and t 
tests. Kaplan-Meier survival curves (17) with Mantel-Haenszel 
(17) log rank statistics were used to compare the rate of 
arrhythmic deaths and total mortality occurring in the two 
groups over the course of the CAST study. 
To control for baseline differences between the two groups, 
Cox proportional hazards models (17) were used to consider 
the two end points: arrhythmic death and total death. The 
following explanatory variables were included in each model: 
age, gender, ejection fraction (assessed by either ventriculog- 
raphy, nuclear techniques or echocardiography), history of 
myocardial infarction (before the CAST qualifying myocardial 
infarction), history of congestive heart failure (assessed by 
standard clinical criteria with use of the New York Heart 
Association classification) and CAST treatment group (active 
treatment vs. placebo), history of diabetes, history of coronary 
artery, angioplasty or bypass grafts, the use of thrombolytic 
agents during the CAST qualifying myocardial infarction, 
coronary artery bypass urgery after the qualifying myocardial 
infarction, the rate of ventricular premature depolarizations/h, 
the presence of new anterior Q waves, the presence of cardiac 
complications during the baseline hospital stay, baseline use of 
calcium channel blockers and the smoking status variable. 
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These variables were included either because they are known 
to be associated with arrhythmic mortality in CAST or because 
they differ significantly for smokers and quitters. Because some 
patients changed their smoking status after the 4-month 
follow-up period, "smoke" was made a time-dependent vari- 
able that changed if a patient reported a different smoking 
status at a subsequent follow-up. Thus, patients who had 
stopped smoking by the time of their 4-month follow-up visit 
but had started again and were active smokers at the follow-up 
visit preceding death were first counted as quitters and then, 
after they started smoking, as smokers. Similarly, patients who 
smoked through the time of their 4-month visit were first 
counted as smokers and then as quitters if they were no longer 
smoking at the clinic visit before death. Because smoking 
status was highly associated with revascularization at the time 
of the CAST qualifying myocardial infarction, the effect of 
smoking was considered separately for patients who did or did 
not have thrombolysis or bypass surgery at the time of the 
qualifying infarction. 
The data were examined in several patient subgroups based 
on the following variables: age, gender, history of myocardial 
infarction (before the qualifying infarction), history of conges- 
tive heart failure, history of diabetes meilitus, treatment group 
(active medication or placebo), ejection fraction and the 
presence of runs of ventricular tachycardia on the qualifying 
Holter recording. Unadjusted arrhythmic death rates were 
compared for the various ubgroups by using chi-square statis- 
tics. Throughout this report, results are considered statistically 
significant when p < 0.05 except for the subgroup analyses, 
when p < 0.01 is required for statistical significance. 
Results 
Table 1 shows the baseline clinical and ECG characteristics 
of our study sample. Of the 1,026 patients who were active 
smokers up to the time of their qualifying myocardial infarc- 
tion, 517 stopped smoking before their 4-month follow-up visit 
("quitters") and 509 continued smoking (present "smokers"). 
The groups are comparable in a wide variety of characteristics 
but show some differences. For example, a significantly higher 
proportion of present smokers had a previous history of 
myocardial infarction and congestive heart failure whereas a 
higher proportion of quitters had a new anterior wall myocar- 
dial infarction, had received thrombolytic agents, had peri- 
infarct complications and had coronary artery bypass urgery 
after their CAST qualifying myocardial infarction. The mean 
follow-up period was 497 _+ 366 days for the quitters and 488 _+ 
357 days for the smokers. 
As assessed by the 4-month smoking status, the quitters had 
17 arrhythmic deaths and 32 deaths overall, whereas the 
smokers had 30 arrhythmic and 45 total deaths. Survival curves 
comparing the smokers and quitters are significantly different 
for arrhythmic death/cardiac arrest (p = 0.04, Fig. 1) and 
display a trend for total survival (p = 0.066, Fig. 2). After 2 
years, the estimated rate of survival from arrhythmic death for 
Table 1. Baseline Characteristics of the Study Group 
"Quitters . . . .  Smokers" p 
(n - 517) (n = 509) Value 
Age (yr) 58.5 _+ 10 57.0 _+ 10 NS 
Male 81.8% 85.3% NS 
CAST active treatment 50.5% 51.5% NS 
Prior MI 29.6% 39.7% 0.001 
Prior CHF 8.3% 14.3% 0.002 
Hypertension 28.0% 28.1% NS 
Diabetes 14.3% 13.9% NS 
Smoked 1 to 20 - -  83.7% - -  
cigarettes daily 
Cigarettes smoked at 25.3 23.7 NS 
baseline (no.) 
Qualifying ECG 
Heart rate (beats/min) 74.3 _+ 16 74.5 _+ 14.4 NS 
ST depression _>1 mm 28.7% 29.2% NS 
New anterior Q waves 30.1% 20.1% 0.001 
QT interval (s) 0.385 + 0.04 0.385 _+ 0.04 NS 
Qualifying Holter 
VPD/h (no.) 118 _+ 231 148 _+ 288 NS 
VT runs present 23.8% 27.3% NS 
Median time from 41.0 40.0 NS 
qualifying MI to 
qualifying Holter 
(days) 
Ejection fraction 36.5 _+ 10 36.7 _+ 10 NS 
Prior CABG/PTCA 11.2% 19.4% 0.001 
Complications during 31.4% 21.2% 0.001 
hospital stay 
Thrombolytic agents 37.7% 28.9% 0.003 
since MI 
PTCA since MI 19.0% 20.0% NS 
CABG since MI 21.3% 13.4% 0.001 
Beta-blockers 29.2% 30.3% NS 
Calcium channel blockers 41.8% 50.5% 0.01 
Digitalis 22.2% 20.4% NS 
Diuretic drugs 30.4% 32.8% NS 
Unless otherwise indicated, data are presented as mean value -- SD or 
percent of patients. CABG = coronary artery bypass graft surgery; CAST = 
Cardiac Arrhythmia Suppression Trial; CHF = congestive heart failure; ECG = 
electrocardiogram; MI = myocardial infarction; PTCA = percutaneous translu- 
minal corona~ angioplasty; VPD = ventricular premature depolarizations; VT 
runs = three or more consecutive ventricular premature depolarizations at a rate 
-> 120 beats/min. 
smokers versus quitters was 89% versus 94%; for total survival, 
the figures were 85% and 91%, respectively. 
By univariate Cox regression analysis, continuing to smoke 
is highly associated with arrhythmic and total mortality (p = 
0.0078 and p = 0.12, respectively). However, after adjustment 
for additional covariates in the multivariate Cox proportional 
hazards models, and using smoking as a time-dependent 
variable (104 of 1,026 patients [10.1% of the sample] changed 
smoking status during the follow-up period), the association 
between continuing to smoke and arrhythmic and total mor- 
tality is of only marginal statistical significance (p = 0.095 and 
p = 0.062, respectively). The hazards ratio is 1.80 (95% 
confidence interval [CI] 0.88 to 3.67) for arrhythmic mortality 
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Figure 1. Kaplan-Meier curves for survival free of arrhythmic death or 
resuscitated cardiac arrest for present "smokers" (solid line) and 
"quitters" (dashed line). Time is measured in years; N refers to the 
number of patients at risk at 0, 1 and 2 years; and Survival is the 
Kaplan-Meier estimate of survival from arrhythmic death or resusci- 
tated cardiac arrest at 0, 1 or 2 years. The two curves are significantly 
different (log rank statistic 4.21, p = 0.040). 
and 1.64 (95% CI 0.97 to 2.79) for total mortality. Specifically, 
the use of thrombolytic agents at the time of the qualifying 
myocardial infarction or subsequently undergoing coronary 
artery bypass urgery, or both, appears to be a confounding 
covariable. In fact, the 558 patients who underwent either of 
these interventions constituted an especially high risk subset 
with 62 deaths (38 arrhythmic) compared with only 15 deaths 
among the 468 patients having one or both interventions (the 
558 patients with no intervention do appear to be older and 
"sicker" with a significantly lower ejection fraction and a 
higher incidence of angina, diabetes, diuretic use, atrial ar- 
rhythmias, premature ventricular beats, history of congestive 
heart failure and prior myocardial infarction) (Table 2). We 
examined smoking cessation in this high risk cohort by using 
the multivariate Cox proportional hazards model where we 
controlled for the same variables in the high risk cohort as we 
did for the entire group. In this model, smoking cessation 
Figure 2. Kaplan-Mcier curves for survival free of death or resusci- 
tated cardiac arrest (total mortality) for present "smokers" (solid line) 
and "quitters" (dashed line). The two curves are not significantly 
different but show a trend (log rank statistic 3.37, p = 0.066). Format 
as in Figure 1. 
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Table 2. Baseline Characteristics of the High Risk Cohort 
"Quitters . . . .  Smokers" p 
(n = 246) (n = 309) Value 
Age (yr) 59.6 +_ 10 58.7 _+ 10 NS 
Male 79.4% 83.5% NS 
CAST active treatment 51.6% 50.6% NS 
Prior M1 31.5% 43.2% 0.001 
Prior CHF 10.9% 17.4% 0.03 
Hypertension 30.2% 30.6% NS 
Diabetes 19.0% 15.8% NS 
Qualifying ECG 
ST depression ->l mm 32.5% 30.2% NS 
New anterior Q waves 26.4% 20.2% NS 
QT interval (s) 0.386 _+ 0.043 0.389 _+ 0.042 NS 
Qualifying Holter 
VPD/~ (no.) 139 _+ 282 156 _+ 279 NS 
VT runs present 22.3 25.1 NS 
Ejection fraction (%) 36.4 _+ 11 36.1 _+ 11 NS 
Prior CABG/FFCA 12.9% 19.0% NS 
Complications during 28.5% 21.4% NS 
hospital stay 
Beta-blockers 31.5% 30.0% NS 
Calcium channel 50.4% 58.1% NS 
blockers 
Digitalis 20.2°,~ 19.4% NS 
Diuretic drugs 33.9% 38.4% NS 
Unless otherwise indicated, data are expressed as mean value _+ SD or 
percent of patients. Abbreviations as in Table 1. 
appears to be of major benefit (p = 0.067 for arrhythmic 
deaths and p -- 0.012 for total mortality). In the high risk 
cohort, the hazard ratios for continuing to smoke are 2.06 
(95% CI 0.92 to 4.61) for arrhythmic mortality and 2.13 (95% 
CI 1.16 to 3.91) for total mortality. The small number of fatal 
events in the patients who had thrombolysis or bypass urgery 
(the "low risk" cohort) precludes meaningful statistical analy- 
sis. 
With two exceptions, there were fewer arrhythmic deaths 
among the quitters in all other subgroups examined, and this 
difference was especially prominent inpatients with an ejection 
fraction <30% and in patients with runs of ventricular tachy- 
cardia on the baseline Holter ECG. Among women and 
patients with diabetes, those classified as quitters had slightly 
more arrhythmic deaths than those classified as smokers, but 
both of these subgroups were extremely small. 
Discussion 
The major finding of the present study is that he benefits of 
smoking cessation are apparent, even in a relatively brief 
follow-up period, in a sample selected specifically for high risk 
of arrhythmic death. The negative outcome of the patients 
receiving active treatment (antiarrhythmic drugs as opposed to 
placebo) has been reported previously (18-20). It is interest- 
ing, then, that the beneficial effects of smoking cessation 
appear to be comparable in the placebo and the active 
treatment groups. Although smoking cessation was associated 
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with a marked reduction in overall mortality and arrhythmic 
death, this decrease was relatively unimpressive in patients 
who had received thrombolytic agents in the course of their 
qualifying myocardial infarction or had subsequently under- 
gone coronary artery bypass urgery, or both, perhaps because 
of the very. small number of events in this subgroup. In 
contrast, patients who had neither of these interventions 
exhibited a major benefit from smoking cessation. Similarly, 
quitters with a low ejection fraction and those with runs of 
ventricular tachycardia on the baseline Holter ECG, who also 
constitute a high risk subset, had an especially good outcome 
compared with that of patients who continued smoking. 
These findings imply that smoking cessation is of particular 
benefit to patients at highest risk of arrhythmic death, and they 
suggest an interaction between an arrhythmogenic substrate 
and the deleterious (and presumably proarrhythmic) effects of 
cigarette smoking. Thus, smoking cessation would appear to be 
a particularly important aspect of risk factor modification in 
patients with the most advanced ischemic heart disease. Ben- 
eficial effects of smoking cessation were not observed in 
women, or in patients with diabetes. However, the small 
number of patients in these two subgroups precludes definitive 
conclusions. Of interest is work by Moyet al. (21) and Howard 
and Howard (22), who found cigarette smoking in diabetic 
women to have an especially negative prognostic impact. 
Perhaps the adverse ffects of smoking in this group of patients 
persist for a longer period of time. 
Cigarette smoking has been demonstrated to produce a 
variety of harmful cardiovascular effects that may be attenu- 
ated or even reversed by smoking cessation. Smoking has been 
shown to increase platelet adhesiveness and serum fibrinogen 
levels, to decrease high density lipoprotein cholesterol levels, 
to transiently diminish the lumen diameter of coronary arteries 
and to increase the rate of atherogenesis, in part by the 
generation of carbon monoxide, a substance that interferes 
with oxygen transport and may directly injure vascular endo- 
thelium (7,23-29). Cardiovascular mortality and the incidence 
of acute myocardial infarction have been shown gradually to 
diminish after smoking cessation, both in subjects with and 
without clinically manifest ischemic heart disease (9-16). 
Similarly, Hallstrom and coworkers (29) describe 310 persons 
with aborted sudden cardiac death whose recurrence rate over 
a 4-year (mean) follow-up period was related to continued 
smoking. The relation between cigarette smoking and arrhyth- 
mias is less clear. Davis et al. (30) used 24-h ambulatory ECG 
monitoring to evaluate the effects of 1 h of smoking and failed 
to find any relation between cigarette smoking and ventricular 
arrhythmias. Our study documents a marked reduction in 
overall mortality and the incidence of arrhythmic death over a 
1-year (mean) period in a large cohort of particularly high risk 
persons. It is possible that other factors, such as acute myo- 
cardial ischemia nd increases in sympathetic nervous ystem 
tone, may interact synergistically with smoking to initiate the 
fatal event. 
Limitations of the study. Our data must be interpreted in
the light of certain methodologic limitations. The positive 
effects of smoking cessation for our entire study group was 
of marginal statistical significance, with major benefit occur- 
ring primarily in those persons at highest risk. Thus, our 
study did not have sufficient power to detect a difference in 
outcome between the two major study groups. Similarly, the 
low event rate in lower risk patients precludes any definitive 
statement about the benefits of smoking cessation in this 
group. Future studies involving a larger number of patients 
and a longer follow-up eriod will be necessary todetermine 
whether smoking cessation is beneficial in all patients after 
myocardial infarction or merely in selected subgroups. Our 
classification of quitter or present smoker was based solely 
on patient interviews and not confirmed by serum nicotine 
or cotinine concentrations. It is probable that this bias may, 
if anything, have caused an underestimation f the benefits 
of smoking cessation because it is more likely that patients 
would underestimate the number of cigarettes smoked or 
underreport continued smoking (continue to smoke surrep- 
titiously) than they would underreport smoking cessation. 
Our definition of quitters is necessarily somewhat arbi- 
trary-that is, those who stopped smoking between the time 
of their qualifying myocardial infarction and their 4-month 
follow-up visit. Because the length of time required for the 
adverse effects of smoking to dissipate is unknown, it is 
possible that some of the events among the quitters were 
smoking related. 
Unlike some workers, we failed to find a relation between 
fatal events and the number of cigarettes smoked, perhaps 
because 84% of our patients moked -<1 pack of cigarettes 
daily. Another study limitation is that serial 24-h ambulatory 
ECGs were not obtained routinely during the follow-up eriod. 
Correlation of smoking status with the frequency of arrhyth- 
mias would be instrumental in delineating the relation between 
smoking and arrhythmic death. We did obtain 24-h ambulatory 
ECGs at the 4-month follow-up visit in a randomly selected 
subset of patients (there were 112 smokers and 122 quitters in 
this subset) and found a slight trend indicating that quitters 
had a greater decrease inventricular ectopic activity during the 
1st 4 months of CAST therapy than did smokers (p = 0.11). 
Lastly, our sample was highly selected so that our data may not 
be applicable to persons without ischemic heart disease, left 
ventricular dysfunction and frequent ventricular ectopic activ- 
ity. 
Summary and conclusions. In summary, our analysis of the 
large and carefully followed up population of the CAST study 
revealed that smoking cessation was accompanied by a major 
reduction in the incidence of arrhythmic death and total 
mortality. The reduction in mortality achieved statistical sig- 
nificance in the cohort at greatest risk of arrhythmic death. 
These data imply that cigarette smoking, probably in conjunc- 
tion with other factors, may be dangerously arrhythmogenic, 
and they emphasize the importance of smoking cessation in 
risk factor eduction in patients with advanced ischemic heart 
disease. 
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